|AI Robots Name||P/L|
BNTX saw its Momentum Indicator move above the 0 level on October 03, 2022. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 47 similar instances where the indicator turned positive. In 43 of the 47 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
The Moving Average Convergence Divergence (MACD) for BNTX just turned positive on September 30, 2022. Looking at past instances where BNTX's MACD turned positive, the stock continued to rise in of 24 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BNTX advanced for three days, in of 195 cases, the price rose further within the following month. The odds of a continued upward trend are .
BNTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for BNTX entered a downward trend on September 22, 2022. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.008) is normal, around the industry mean (26.140). P/E Ratio (3.082) is within average values for comparable stocks, (91.441). Projected Growth (PEG Ratio) (0.046) is also within normal values, averaging (3.845). Dividend Yield (0.013) settles around the average of (0.026) among similar stocks. P/S Ratio (1.709) is also within normal values, averaging (292.549).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. BNTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
|Technical Analysis||# Of Indicators||Avg. Odds|
a company, which focuses on the development of molecular immune therapies and biomarker-based diagnostic approaches
A.I.dvisor indicates that over the last year, BNTX has been closely correlated with MRNA. These tickers have moved in lockstep 84% of the time. This A.I.-generated data suggests there is a high statistical probability that if BNTX jumps, then MRNA could also see price increases.
|MRNA - BNTX|
|CVAC - BNTX|
|VIR - BNTX|
|ARCT - BNTX|
|MRVI - BNTX|